Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 22 for “"Benign prostatic hyperplasia"”.
-
Development of Feedback Microwave Thermotherapy in Symptomatic Benign Prostatic Hyperplasia.
… and safety in the treatment of patients with benign prostatic hyperplasia (BPH). The application of two biophysical equations in the PLFT software is explained. The calculations provide the intraprostatic ?blood flow index? and amount of accumulated coagulation necrosis during treatment. The …
-
Does Mondia whitei play a role in the treatment of prostate cancer and benign prostatic hyperplasia?
Prostate cancer and benign prostatic hyperplasia are two of the most prevalent urological disorders affecting aging men worldwide. Conventional treatments including androgendeprivation therapy, 5α-reductase inhibitors, and surgery, are effective but often associated with adverse effects that …
-
Evaluating diagnostic and treatment modalities in the management of benign prostatic hyperplasia in the Veterans Administration population
Benign prostatic hyperplasia (BPH), a common prostatic condition among aging males significantly affects quality of life. Though clinical practice guidelines for BPH management have been established, little research has been done to determine adherence to such guidelines. To assess adherence to …
-
Hormonální profil u mužů s lokalizovaným a lokálně pokročilým karcinomem prostaty
… environment in men with prostate cancer and benign prostatic hyperplasia.
-
Characterization of a Novel Prostate Tumor-Associated Antigen
… to detect antigens that are heavily expressed by benign prostatic hyperplasia (BPH) and carcinoma of the prostate (CaP). Western blot analysis of prostate extracts, showed that MAb TURP-27 and MAb HNK-1 bound glycoproteins of 180, 140, 120, 100, 90 and 69 kDa. Studies have shown that the HNK-1 …
-
Ruolo dei neurosteroidi nella modulazione dopaminergica
… (FIN), is currently approved for the therapy of benign prostatic hyperplasia and androgenic alopecia. We found that, in rodents, FIN attenuates the severity of behavioral manifestations induced by dopaminergic agents, including deficits of sensorimotor gating as well as repetitive and compulsive …
-
Alpha-Blocker Treatment Response in Men with Lower Urinary Tract Symptoms Based on Sympathetic Activity : Prospective, Multicenter, Open - Labeled, Observational Study
… with lower urinary tract symptoms resulting from benign prostatic hyperplasia were analyzed. We assigned patients to groups according to their sympathetic activity, which was evaluated by heart rate variability measurements. HSA was defined as a low frequency/high frequency ratio greater than 1.6. …
-
Altered Cholesterol Metabolism In Human Cancers Unraveled By Label-Free Spectroscopic Imaging
… and metastases, but not in normal prostate, benign prostatic hyperplasia, or prostatitis. Biochemical and molecular biological studies showed that such cholesteryl ester accumulation was a consequence of loss of tumor suppressor PTEN and subsequent activation of PI3K/AKT pathway in prostate …
-
Analysis of N-Linked Oligosaccharides of Prostate-Specific Antigen and Prostatic Acid Phosphatase in Prostatic Fluids
… in non-cancerous conditions as well, such as benign prostatic hyperplasia (BPH). Due to this overlap, many unnecessary biopsies and radical prostatectomies occur, leading to patient distress. Despite recent advances to clinical assays which consider other clinical parameters, there is still a …
-
Prostate Cancer and the Search for Novel Biomarkers
… with enlarged, non-cancerous prostates or with Benign Prostatic Hyperplasia (BPH). Urine samples were also collected from the same patients (PCa and BPH) as part of a two-year follow-up. Initially urinary nucleic acids and proteins were assessed both qualitatively and quantitatively for …
-
Purification and Characterization of the Prostate Cancer-Associated Antigen: 7E11-C5
… cell line, LNCaP, and tissue extracts of benign prostatic hyperplasia (BPH) and prostate carcinomas, but was not identified in any of the non-prostate tissue extracts tested. Antibodies of the three major prostate-associated antigens (prostatic acid phosphatase (PAP), prostate specific …
-
Novel urinary and serological markers of prostate cancer using proteomics techniques: an important tool for early cancer diagnosis and treatment monitoring
… We compared the urinary proteomes of PCa, Benign Prostatic Hyperplasia (BPH), disease controls comprising patients with other uropathies (DC) and normal healthy controls (NC) both by pooling and individual discovery shotgun proteomic assessment on a nano-Liquid chromatography (nLC) coupled …
-
Characterisation of novel alpha1-adrenoceptor ligands
… to treat urogenital conditions, such as benign prostatic hyperplasia, have side effects due to a lack of subtype selectivity and the 5-HT1A-R off-target affinity. In this study, computer-aided drug design, structure-activity relationship, and molecular pharmacology methods were used to …
-
Cell-free DNA and tumor exosome cargo as diagnostic and prognostic marker for prostate cancer
… of high and low Gleason's score PCa samples and benign prostatic hyperplasia (BPH). We also performed whole exome sequencing of urinary cell free DNA and we identified 31 mutated genes. We reported for the first time an association between 27 of these genes and PCa in African populations. Four of …
-
Biospectroscopy towards screening and diagnosis of cancer
… spatial and temporal mammary alterations in benign tissue. Prostate cancer is influenced by environmental factors. Its incidence is higher in populations adopting a Westernised lifestyle and diet and has increased over the past generation. This leads to the assumption that prostatic tissue …
-
Lineage tracing of normal human development and childhood cancers
… as well as later clonal expansions such as benign prostatic hyperplasia and neoplastic polyp formation. In a similar way, I also used somatic mutations to investigate the emergence of paediatric cancer, which is thought to be closely linked to aberrations in development. In the context of …
-
Towards the development of fluorescent probes targeting aldehyde dehydrogenase (ALDH) in cancer. Expression and epigenetic modulation of ALDH1A1, ALDH2 and ALDH3A1 in selected in vitro models.
… were found in primary prostate cancer cells and benign prostatic hyperplasia. Interestingly, ALDH1A1, considered a SC marker, was found to be expressed at low levels in CD133+/ α2β1hi stem cell fraction and upregulated in CD133-= α2β1lo differentiated prostate cancer cells. In summary, the …
-
Towards the development of fluorescent probes targeting aldehyde dehydrogenase (ALDH) in cancer. Expression and epigenetic modulation of ALDH1A1, ALDH2 and ALDH3A1 in selected in vitro models.
… were found in primary prostate cancer cells and benign prostatic hyperplasia. Interestingly, ALDH1A1, considered a SC marker, was found to be expressed at low levels in CD133+/ α2β1hi stem cell fraction and upregulated in CD133-= α2β1lo differentiated prostate cancer cells. In summary, the …
-
Identifying genetic biomarkers for diagnosis of prostate cancer in South African men
… distinguishing patients with PCa from those with benign prostatic hyperplasia (BPH). These include fractionated PSA, free/total PSA ratio, −2proPSA, prostate cancer antigen 3 and prostate health index amongst others. Biomarkers are needed to differentiate BPH from PCa due to a lack of specificity …
-
Proteomic Profiling of Serum Derived Exosomes from Prostate Cancer Patients
… by about a decade was the introduction of Prostatic Specific Antigen (PSA) into clinical practice; first as biomarker for monitoring response to therapy and subsequently as a complementary screening tool. It is not surprising then that a cause-effect relationship has been suggested. Like a …
Page 1 of 2